Hi-Tech Pharmacal: Acquires licensing rights to a dietary supplement called Huperzine and its analogs in the U.S., Canada and Europe from the Mayo Clinic in Rochester, Minn. Hi-Tech is planning to conduct clinical trials in the U.S. on Huperzine, a Chinese folk remedy that has been shown to inhibit the enzyme responsible for the breakdown of acetylcholine, a neurotransmitter believed to be important in learning and memory. The natural compound is derived from the club moss Huperzine serrata. "Results suggest" that Huperzine "improves learning and memory in certain patients. However, these suggested results have not been substantiated by clinical trials," Amityville, N.Y.-based Hi-Tech says...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.
Madrigal Pharmaceuticals’ Rezdiffra is on track to become the first medicine approved in the EU for non-cirrhotic metabolic dysfunction-associated steatohepatitis after the European Medicines Agency recommended that it be granted conditional marketing authorization.
Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.
